Citrate containing beverage
AssigneesNew York University, The General Hospital Corporation, The Regents of the University of California
InventorsDavid S. GOLDFARB, Brian EISNER, John ASPLIN, Marshall L. STOLLER
Life of this patent
Estimating the term…
Abstract
Provided are beverage compositions comprising a urine citrate increasing component and a urine oxalate reducing component. The beverage compositions may be provided in a ready-to-drink form or may be provided in a concentrate form. Also provided are kits comprising the beverage compositions and methods for treating various conditions using the beverage compositions.
Claims26
A beverage comprising sodium citrate, potassium citrate, citric acid, magnesium salt and pyridoxine.
A beverage comprising:
- (1) 1.0 to 4.0 mmol/L sodium citrate;
- (2) 3.0 to 7.5 mmol/L potassium citrate;
- (3) 15 to 25 mmol/L citric acid;
- (4) 1 to 3 mmol/L magnesium hydroxide;
- and
- (5) 1.5-3.5 mg/L pyridoxine,
- wherein the pH of the beverage is 3.3-7.0.
A beverage comprising:
- (1) 3.33 mmol/L sodium citrate
- (2) 5.0 mmol/L potassium citrate;
- (3) 19.67 mmol/L citric acid;
- (4) 2.0 mmol/L magnesium hydroxide;
- and
- (5) 2.5 mg/L pyridoxine,
- wherein the pH of the beverage is 3.5.
A method for management of kidney stone disease in a human in need thereof comprising administration of a beverage comprising sodium citrate, potassium citrate, citric acid, magnesium hydroxide and pyridoxine.
A method for increasing urinary citrate and/or reducing urinary oxalate by providing a beverage to an individual, said beverage comprising 1 to 4.0 mmol/L sodium citrate;
- 3.0 to 7.5 mmol/L potassium citrate;
- 15 to 25 mmol/L citric acid;
- 1 to 3 mmol/L magnesium hydroxide;
- and 1.5-3.5 mg/L pyridoxine, wherein the pH of the beverage is 3.3-7.0.
A method for increasing urinary citrate and/or reducing urinary oxalate by providing a beverage to an individual, said beverage comprising 3.33 mmol/L sodium citrate;
- 5.0 mmol/L potassium citrate;
- 19.67 mmol/L citric acid;
- 2.0 mmol/L magnesium hydroxide;
- and 2.5 mg/L pyridoxine, wherein the pH of the beverage is 3.5.
A method for management of kidney stones in a human in need thereof comprising administering a beverage to the human, said beverage comprising 1 to 4.0 mmol/L sodium citrate;
- 3.0 to 7.5 mmol/L potassium citrate;
- 15 to 25 mmol/L citric acid;
- 1 to 3 mmol/L magnesium hydroxide;
- and 1.5-3.5 mg/L pyridoxine, wherein the pH of the beverage is 3.3-7.0, wherein said beverage is provided in a volume of 1-2 liters for administration to the individual over a 24 hour period.
A kit comprising:
- (a) a composition provided as a powdered mix, a concentrate or a tablet, said composition comprising sodium citrate, potassium citrate, citric acid, magnesium hydroxide, and pyridoxine in amounts such that a beverage prepared from it will have 1.0 to 4.0 mmol sodium citrate, 3.5 to 7.5 mmol potassium citrate, 15 to 25 mmol citric acid, 1 to 3 mmol magnesium hydroxide, and 1.5 to 3.5 mg pyridoxine per liter, and a pH of 3.3 to 7.0;
- (b) a set of instructions, said instructions describing how to prepare a beverage using the powdered mix, concentrate or the tablet, and describing the frequency and volume of the beverage to be consumed by an individual.
A kit comprising:
- a) a plurality of individually portioned powdered mixes, concentrate or tablet, wherein the contents of each portion when mixed with a preselected amount of water, will make a beverage having 1.0 to 4.0 mmol sodium citrate, 3.5 to 7.5 mmol potassium citrate, 15 to 25 mmol citric acid, 1 to 3 mmol magnesium hydroxide, and 1.5 to 3.5 mg pyridoxine per liter;
- b) the preselected amount of water for making the beverage from the contents of each individual portion or instructions on how much water is required to make said beverage and directions for making said beverage.
A beverage concentrate comprising sodium citrate, potassium citrate, citric acid, magnesium salt and pyridoxine.
Dependencies are inferred from the claim text.